Skip to main content

KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma

User login

Username

Password

Reset your password

Type	Lead	score